Biosimilars Diabetes Hospitals 
PharmaShots
FEBRUARY 1, 2023
Ximluci is expected to be available in the UK in 2023 The approval for Ximluci was granted through the EC decision reliance procedure, whereby the MHRA’s decision was based on the EC Ximluci was approved in the UK for wet AMD, DME, diabetic retinopathy, RVO, and visual impairment due to choroidal neovascularization in adults.
Pharma Leaders
JUNE 15, 2023
Fresenius has invested nearly $1bn for the manufacture as well as distribution of Vasopressin to serve hospitals and health systems in the US. Patients may also suffer from reversible diabetes insipidus after stopping treatment with vasopressin.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Business Review
JUNE 15, 2023
Fresenius has invested nearly $1bn for the manufacture as well as distribution of Vasopressin to serve hospitals and health systems in the US. Patients may also suffer from reversible diabetes insipidus after stopping treatment with vasopressin.
PharmaState Academy
JULY 23, 2023
His wife Neeta along with friends, rush him to Asclepius Hospital. It was a diabetic coma caused by a traditional medicine which inadvertently led to hypoglycemia. Even today, the first line treatment for diabetes is diet and exercise. Suddenly he collapses. This is the fact. It is for you to get it enforced”. “Done Dr. Reddy.”
PharmaShots
FEBRUARY 27, 2023
Addepalli Veeranjaneyulu and Shubhadeep Debabrata Sinha introduced the session by describing the function of PV in the safety profiles of biosimilars. To provide the audience with an Indian viewpoint, the presenters pointed out the country's requirements for biosimilar PV. Dr. Mangesh.
STAT
APRIL 24, 2024
One study from the American Society of Health-System Pharmacists found that GLP-1 treatments were a main driver of the increase in overall drug spending by health entities such as pharmacies and hospitals last year. billion, making the drug the top-selling medicine in 2023. Continue to STAT+ to read the full story…
Putting Patients First Blog
JANUARY 27, 2025
The NHC recognizes that Medicare already covers AOMs for patients who are overweight and have comorbid conditions such as diabetes or cardiovascular disease. To further strengthen these efforts, the NHC recommends that CMS adopt additional measures to ensure broad access to generics, biosimilars, and other cost-effective treatments.
Expert insights. Personalized for you.
40 
Let's personalize your content